Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Simple bladder cancer test

University of Florida researchers have identified a set of proteins that appear to signal the presence of bladder cancer, a discovery they hope will lead to a simple, fast and noninvasive test that can detect the disease early.

9 Jul 2007

Scientists discover first common bowel cancer gene

Cancer Research UK funded scientists have for the first time identified a common genetic variant that can increase a person's risk of developing bowel cancer. Their findings appear in two papers published online in Nature Genetics.

9 Jul 2007

Genome detectives reveal gene suspect for bowel cancer

Scientists in Britain have identified a gene they say increases the risk of bowel cancer by 20%.

8 Jul 2007

Genetic mutation that may alter response to cancer therapeutics found

Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers.

4 Jul 2007

New genetic marker characterizes aggressiveness of cancer cells

Levels of a small non-coding RNA molecule called let-7 appear to define different stages of cancer better than some of the "classical" markers for tumor progression, researchers from the University of Chicago report in the June 25, 2007, early online edition of the Proceedings of the National Academy of Sciences.

26 Jun 2007

Ovarian cancer is not a symptom free disease

Ovarian cancer is not the symptom free disease that many medical textbooks have been claiming for years, says an Editorial in this week’s edition of The Lancet.

23 Jun 2007

Size of family appears to affect breast cancer risk

Researchers have found that the probability of the breast cancer gene mutation BRCA among women with a history of breast cancer is greater when the number of older, female relatives in the family is smaller, according to a study in the June 20 issue of JAMA: The Journal of the American Medical Association.

20 Jun 2007

Doubt cast on reliabilty of current models for breast cancer risk

A new study has challenged the accuracy of models currently used to predict a woman's risk of breast cancer.

20 Jun 2007

Hormone therapy can extend life in ovarian cancer patients

The study, published in Clinical Cancer Research, has proved for the first time that the targeted use of an anti-oestrogen drug could prolong the life of some patients by up to three years, and delay the use of chemotherapy in others.

17 Jun 2007

Double-duty nanoparticles overcome drug resistance in tumors

Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.

14 Jun 2007

Will list of symptoms for ovarian cancer save lives?

The American Cancer Society along with CancerCare, Gilda's Club and several other medical groups have released a consensus statement listing the symptoms for ovarian cancer.

13 Jun 2007

VEGF Trap (aflibercept) shows activity in patients with advanced ovarian cancer

Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.

5 Jun 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

PET plus CT - best test for ovarian cancer

An advanced molecular imaging technique influenced the management of women with ovarian cancer, detected more sites of disease and identified women whose disease was likely to progress, according to an Australian study released during the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

5 Jun 2007

PET accurately identifies esophageal cancer patients' positive responses to chemotherapy

Early metabolic imaging with positron emission tomography (PET) accurately identifies patients responding to chemotherapy for esophageal cancer, noted German researchers at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

5 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Genetic testing helps cancer survivors fight for their loved ones

Family members of those who are successfully fighting cancer are protecting themselves and their families from the disease through genetic testing and hereditary cancer risk assessment.

3 Jun 2007

New candidate breast-cancer susceptibility gene

Researchers at the Abramson Family Cancer Research Institute of the University of Pennsylvania and the Dana-Farber Cancer Institute describe in this week's issue of Science a new candidate breast-cancer susceptibility gene.

28 May 2007

Detailed portrait of 700 proteins that help maintain DNA integrity

Cells have the remarkable ability to keep track of their genetic contents and -- when things go wrong, to step in and repair the damage before cancer or another life-threatening condition develops.

28 May 2007

FDA approves VELCADE plus DOXIL combination for multiple myeloma

Ortho Biotech Products has announced the U.S. Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in combination with VELCADE (bortezomib) for Injection to treat patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy.

23 May 2007